Scholarlink

Objectives <p>To evaluate the feasibility and short-term outcomes of postoperative bladder drainage using a temporary prostatic urethral stent following Rezūm™ therapy.</p> Methods <p>This prospective bicentric pilot study included 32 consecutive patients undergoing Rezūm™ therapy between March 2025 and February 2026. Postoperative bladder drainage was performed using a temporary prostatic stent (CoreFlow™, ProstaLund AB, Sweden). The primary endpoint was overall strategy success, defined as successful device insertion, maintenance until planned removal without conversion to standard urethral catheterisation, and no secondary re-catheterisation.</p> Results <p>Overall strategy success was achieved in 26 of 32 patients (81%). CoreFlow™ stent insertion was successful in 29 patients (91%). Median duration of stenting was 4 days (IQR 4–6). At 30 days after device removal, median patient satisfaction was 8 (IQR 7–9), and median discomfort score was 2 (IQR 1–2). Macroscopic haematuria occurred in 15 patients (47%), urinary retention in 3 (9%), and urinary tract infection in 1 (3%). No device migration or unplanned hospitalisation was observed.</p> Conclusion <p>Temporary prostatic stenting appears to be a feasible and well-tolerated postoperative drainage strategy following Rezūm™ therapy. Larger comparative studies are needed to determine its clinical benefit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bladder drainage using the coreflow prostatic stent after REZUM therapy

  • 期刊论文

  • 发表日期：

    2026年6月25日

查看全文
  • Thibaut Long-Depaquit,
  • Frederica Sordelli,
  • Anne Laure Charvet,
  • Christopher Agüero,
  • Silvia Secco,
  • Clément Sarrazin,
  • Michael Baboudjian,
  • Marc Fourmarier

摘要

Objectives

To evaluate the feasibility and short-term outcomes of postoperative bladder drainage using a temporary prostatic urethral stent following Rezūm™ therapy.

Methods

This prospective bicentric pilot study included 32 consecutive patients undergoing Rezūm™ therapy between March 2025 and February 2026. Postoperative bladder drainage was performed using a temporary prostatic stent (CoreFlow™, ProstaLund AB, Sweden). The primary endpoint was overall strategy success, defined as successful device insertion, maintenance until planned removal without conversion to standard urethral catheterisation, and no secondary re-catheterisation.

Results

Overall strategy success was achieved in 26 of 32 patients (81%). CoreFlow™ stent insertion was successful in 29 patients (91%). Median duration of stenting was 4 days (IQR 4–6). At 30 days after device removal, median patient satisfaction was 8 (IQR 7–9), and median discomfort score was 2 (IQR 1–2). Macroscopic haematuria occurred in 15 patients (47%), urinary retention in 3 (9%), and urinary tract infection in 1 (3%). No device migration or unplanned hospitalisation was observed.

Conclusion

Temporary prostatic stenting appears to be a feasible and well-tolerated postoperative drainage strategy following Rezūm™ therapy. Larger comparative studies are needed to determine its clinical benefit.